American Century Companies’s C4 Therapeutics CCCC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$704K Buy
150,681
+65,237
+76% +$223K ﹤0.01% 2509
2026
Q1
$225K Buy
85,444
+17,199
+25% +$40.5K ﹤0.01% 2688
2025
Q4
$130K Buy
68,245
+43,997
+181% +$104K ﹤0.01% 2744
2025
Q3
$53.8K Buy
+24,248
New +$58.2K ﹤0.01% 2771
2025
Q2
Sell
-141,986
Closed -$227K 2867
2025
Q1
$227K Buy
141,986
+9,154
+7% +$27.3K ﹤0.01% 2732
2024
Q4
$478K Buy
132,832
+10,459
+9% +$52K ﹤0.01% 2527
2024
Q3
$698K Buy
122,373
+12,298
+11% +$74K ﹤0.01% 2360
2024
Q2
$509K Buy
110,075
+21,225
+24% +$127K ﹤0.01% 2432
2024
Q1
$726K Buy
88,850
+54,116
+156% +$419K ﹤0.01% 2282
2023
Q4
$196K Buy
34,734
+2,938
+9% +$6.7K ﹤0.01% 2701
2023
Q3
$59.1K Buy
31,796
+7,843
+33% +$23.9K ﹤0.01% 2788
2023
Q2
$65.9K Buy
23,953
+9,292
+63% +$29.9K ﹤0.01% 2745
2023
Q1
$45.4K Buy
14,661
+2,675
+22% +$15.7K ﹤0.01% 2632
2022
Q4
$70.7K Buy
+11,986
New +$99.4K ﹤0.01% 2505

Other funds holding CCCC

American Century Companies's CCCC Position: Q2 2026 in Review

American Century Companies increased its C4 Therapeutics (CCCC) stake by 76% in Q2 2026, buying an estimated $223K and bringing the position to 150,681 shares worth $704K. The position accounts for ﹤0.01% of the portfolio, ranked #2509.

American Century Companies first reported a position in CCCC in Q4 2022 and has held it in 14 quarters since. The position peaked at $726K in Q1 2024. 85 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

  • American Century Companies held 150,681 shares of C4 Therapeutics worth $704K as of Q2 2026.
  • American Century Companies bought 65,237 C4 Therapeutics shares in Q2 2026, an estimated $223K.
  • C4 Therapeutics made up ﹤0.01% of American Century Companies's portfolio in Q2 2026, its #2509 holding.
  • American Century Companies first reported a position in C4 Therapeutics in Q4 2022 and has held it in 14 quarters since.
  • American Century Companies's C4 Therapeutics position peaked at $726K in Q1 2024.
  • 85 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on American Century Companies's 13F filing for Q2 2026, filed 12 Aug 2026.